Previous 10 | Next 10 |
FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib PR Newswire Curis working with clinical sites to resume enrollment Preliminary clinical data update expected in 2023 LEXINGTON, Mass. , Aug. 18, 2022 /PRNewswire/...
Curis, Inc. (CRIS) Q2 2022 Earnings Conference Call August 04, 2022, 16:30 ET Company Participants Craig West - VP, IR & Corporate Communications Jim Dentzer - President & CEO Bill Steinkrauss - CFO & Chief Administrative Officer Conference Call...
Image source: The Motley Fool. Curis (NASDAQ: CRIS) Q2 2022 Earnings Call Aug 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Curis (CRIS) Q2 2022 Earnings Call Transcript
Curis press release ( NASDAQ: CRIS ): Q2 GAAP EPS of -$0.17 in-line. Revenue of $2.39M (+3.9% Y/Y) misses by $0.33M . For further details see: Curis GAAP EPS of -$0.17 in-line, revenue of $2.39M misses by $0.33M
Curis Reports Second Quarter 2022 Financial Results and Business Update PR Newswire Presented encouraging clinical data for the combination of emavusertib plus ibrutinib showing tumor reduction in 8 of 9 evaluable patients and the potential for overcoming ibrutinib res...
The following slide deck was published by Curis, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Curis, Inc. 2022 Q2 - Results - Earnings Call Presentation
Curis ( NASDAQ: CRIS ) is scheduled to announce Q2 earnings results on Thursday, August 4th, after market close. The consensus EPS Estimate is -$0.17 and the consensus Revenue Estimate is $2.72M (+18.3% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward r...
Curis Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) PR Newswire LEXINGTON, Mass. , July 29, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of...
Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022 PR Newswire LEXINGTON, Mass. , July 28, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovativ...
Curis share price has had dramatic fall since the FDA announced a hold on their “TakeAim” Leukemia study for Emavusertib on April 4, 2022, following the death of a patient. Recent price action since bottoming has been much more constructive and seems to show accumulation...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Curis to Present at Upcoming Healthcare Conference in July PR Newswire LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IR...
2024-05-25 08:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...